Publicacions en què col·labora amb José Luis Pérez Gracia (30)

2020

  1. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

2018

  1. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

  2. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319

2017

  1. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

    Annals of Oncology, Vol. 28, Núm. 8, pp. 1988-1995

  2. Interleukin-8 in cancer pathogenesis, treatment and follow-up

    Cancer Treatment Reviews, Vol. 60, pp. 24-31

2016

  1. Tumor-Produced Interleukin-8 Attracts human myeloid-derived suppressor cells and elicits extrusion of Neutrophil Extracellular Traps (NETs)

    Clinical Cancer Research, Vol. 22, Núm. 15, pp. 3924-3936

2015

  1. Functional expression of CD137 (4-1BB) on T helper follicular cells

    OncoImmunology, Vol. 4, Núm. 12

  2. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice

    Cancer Research, Vol. 75, Núm. 17, pp. 3466-3478

2014

  1. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins

    Clinical Cancer Research, Vol. 20, Núm. 22, pp. 5697-5707

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88

  2. Células dendríticas especializadas en presentación de antígenos exógenos a linfocitos T citotóxicos

    Anales del sistema sanitario de Navarra, Vol. 36, Núm. 3, pp. 519-537

2012

  1. Cardiotrophin-1 determines liver engraftment of syngenic colon carcinoma cells through an immune system-mediated mechanism

    OncoImmunology, Vol. 1, Núm. 9, pp. 1527-1536

  2. The HIF-1α hypoxia response in tumor-infi ltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy

    Cancer Discovery, Vol. 2, Núm. 7, pp. 608-623

2011

  1. Carcinoma-derived Interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation

    PLoS ONE, Vol. 6, Núm. 3

  2. Dendritic cells take up and present antigens from viable and apoptotic polymorphonuclear leukocytes

    PLoS ONE, Vol. 6, Núm. 12

  3. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients

    Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142

  4. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo

    International Journal of Cancer, Vol. 129, Núm. 2, pp. 374-386

2010

  1. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

    Cancer Immunology, Immunotherapy, Vol. 59, Núm. 8, pp. 1223-1233

2009

  1. Clinical development of combination strategies in immunotherapy: Are we ready for more than one investigational product in an early clinical trial?

    Immunotherapy, Vol. 1, Núm. 5, pp. 845-853

  2. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

    European Journal of Immunology, Vol. 39, Núm. 9, pp. 2424-2436